Literature DB >> 12810547

Human type 3 3alpha-hydroxysteroid dehydrogenase (aldo-keto reductase 1C2) and androgen metabolism in prostate cells.

Tea Lanisnik Rizner1, Hsueh K Lin, Donna M Peehl, Stephan Steckelbroeck, David R Bauman, Trevor M Penning.   

Abstract

Human aldo-keto reductases (AKRs) of the AKR1C subfamily function in vitro as 3-keto-, 17-keto-, and 20-ketosteroid reductases or as 3alpha-, 17beta-, and 20alpha-hydroxysteroid oxidases. These AKRs can convert potent sex hormones (androgens, estrogens, and progestins) into their cognate inactive metabolites or vice versa. By controlling local ligand concentration AKRs may regulate steroid hormone action at the prereceptor level. AKR1C2 is expressed in prostate, and in vitro it will catalyze the nicotinamide adenine dinucleotide (NAD(+))-dependent oxidation of 3alpha-androstanediol (3alpha-diol) to 5alpha-dihydrotestosterone (5alpha-DHT). This reaction is potently inhibited by reduced NAD phosphate (NADPH), indicating that the NAD(+): NADPH ratio in cells will determine whether AKR1C2 makes 5alpha-DHT. In transient COS-1-AKR1C2 and in stable PC-3-AKR1C2 transfectants, 5alpha-DHT was reduced by AKR1C2. However, the transfected AKR1C2 oxidase activity was insufficient to surmount the endogenous 17beta-hydroxysteroid dehydrogenase (17beta-HSD) activity, which eliminated 3alpha-diol as androsterone. PC-3 cells expressed retinol dehydrogenase/3alpha-HSD and 11-cis-retinol dehydrogenase, but these endogenous enzymes did not oxidize 3alpha-diol to 5alpha-DHT. In stable LNCaP-AKR1C2 transfectants, AKR1C2 did not alter androgen metabolism due to a high rate of glucuronidation. In primary cultures of epithelial cells, high levels of AKR1C2 transcripts were detected in prostate cancer, but not in cells from normal prostate. Thus, in prostate cells AKR1C2 acts as a 3-ketosteroid reductase to eliminate 5alpha-DHT and prevents activation of the androgen receptor. AKR1C2 does not act as an oxidase due to either potent product inhibition by NADPH or because it cannot surmount the oxidative 17beta-HSD present. Neither AKR1C2, retinol dehydrogenase/3alpha-HSD nor 11-cis-retinol dehydrogenase is a source of 5alpha-DHT in PC-3 cells.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12810547     DOI: 10.1210/en.2002-0032

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  46 in total

Review 1.  Human hydroxysteroid dehydrogenases and pre-receptor regulation: insights into inhibitor design and evaluation.

Authors:  Trevor M Penning
Journal:  J Steroid Biochem Mol Biol       Date:  2011-01-25       Impact factor: 4.292

Review 2.  The syndrome of 17,20 lyase deficiency.

Authors:  Walter L Miller
Journal:  J Clin Endocrinol Metab       Date:  2011-11-09       Impact factor: 5.958

3.  Development of potent and selective inhibitors of aldo-keto reductase 1C3 (type 5 17β-hydroxysteroid dehydrogenase) based on N-phenyl-aminobenzoates and their structure-activity relationships.

Authors:  Adegoke O Adeniji; Barry M Twenter; Michael C Byrns; Yi Jin; Mo Chen; Jeffrey D Winkler; Trevor M Penning
Journal:  J Med Chem       Date:  2012-02-15       Impact factor: 7.446

Review 4.  Identification of the molecular switch that regulates access of 5alpha-DHT to the androgen receptor.

Authors:  Trevor M Penning; David R Bauman; Yi Jin; Tea Lanisik Rizner
Journal:  Mol Cell Endocrinol       Date:  2007-01-16       Impact factor: 4.102

Review 5.  Intracrinology-revisited and prostate cancer.

Authors:  Trevor M Penning; Andrea J Detlefsen
Journal:  J Steroid Biochem Mol Biol       Date:  2019-10-12       Impact factor: 4.292

Review 6.  The biological actions of dehydroepiandrosterone involves multiple receptors.

Authors:  Stephanie J Webb; Thomas E Geoghegan; Russell A Prough; Kristy K Michael Miller
Journal:  Drug Metab Rev       Date:  2006       Impact factor: 4.518

7.  A 3-(4-nitronaphthen-1-yl) amino-benzoate analog as a bifunctional AKR1C3 inhibitor and AR antagonist: Head to head comparison with other advanced AKR1C3 targeted therapeutics.

Authors:  Phumvadee Wangtrakuldee; Adegoke O Adeniji; Tianzhu Zang; Ling Duan; Buddha Khatri; Barry M Twenter; Michelle A Estrada; Tyler F Higgins; Jeffrey D Winkler; Trevor M Penning
Journal:  J Steroid Biochem Mol Biol       Date:  2019-01-11       Impact factor: 4.292

8.  Human cytosolic hydroxysteroid dehydrogenases of the aldo-ketoreductase superfamily catalyze reduction of conjugated steroids: implications for phase I and phase II steroid hormone metabolism.

Authors:  Yi Jin; Ling Duan; Seon Hwa Lee; Helenius J Kloosterboer; Ian A Blair; Trevor M Penning
Journal:  J Biol Chem       Date:  2009-02-12       Impact factor: 5.157

9.  5alpha-androstane-3alpha,17beta-diol selectively activates the canonical PI3K/AKT pathway: a bioinformatics-based evidence for androgen-activated cytoplasmic signaling.

Authors:  Mikhail G Dozmorov; Qing Yang; Adam Matwalli; Robert E Hurst; Daniel J Culkin; Bradley P Kropp; Hsueh-Kung Lin
Journal:  Genomic Med       Date:  2008-02-27

10.  Lack of functional and expression homology between human and mouse aldo-keto reductase 1C enzymes: implications for modelling human cancers.

Authors:  Pedro Veliça; Nicholas J Davies; Pedro P Rocha; Heinrich Schrewe; Jonathan P Ride; Chris M Bunce
Journal:  Mol Cancer       Date:  2009-12-14       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.